While the administration of denosumab, a receptor activator of nuclear factor-kappa B ligand (RANKL) inhibitor, has been shown to elicit a favorable tumor response in the short term, it can also lead to an elevated risk of tumor recurrence after curettage and may even prompt GCTB to evolve into a more malignant sarcoma [4]. Here, TNFSF11 is linked to sarcoma.